Diabetes device makers fall after data on Lilly's weight loss pill

Shares of diabetes device makers fall between 1% to 3% before the bell

Eli Lilly LLY.N says its oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial

Shares of Dexcom DXCM.O, which manufactures continuous glucose monitors, down 2.6% at $66.94 premarket

Shares of insulin pump makers Tandem Diabetes Care TNDM.O and Insulet Corp PODD.O down around 2% each

LLY shares rise 13.4% to $833.56 premarket

As of last close, DXCM down 11.6%, TNDM down 52.1%, LLY down 4.8%, PODD down 4% YTD